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Schizophrenia is a highly heritable disorder, but many aspects of its etiology and pathophysiology remain
poorly understood. Synaptic pathology has been reported as a feature of the brain in schizophrenia.
Abnormal expression of some synaptic proteins (e.g., SYP, GAP-43, and NRGN) in different brain regions
has been linked to this disorder in postmortem brain studies. In our series of genetic studies, we used
a resequencing strategy to search for genetic variants in these candidate genes in a sample of patients
with schizophrenia and nonpsychotic controls, all of whom were Han Chinese from Taiwan, and con-
ducted further association and functional studies. After resequencing these candidate genes, no common
polymorphisms appeared to play a major role in conferring susceptibility to schizophrenia in our pop-
ulation. In contrast, we identiﬁed some rare patient-speciﬁc variants. The results of the reporter gene
assays and software analysis demonstrated the inﬂuence of reporter genes on the function of each
studied gene, suggesting that they may contribute to the pathogenesis of schizophrenia. These data lend
support to the hypothesis that multiple rare mutations are involved in the pathogenesis of schizophrenia,
and provide genetic clues that indicate the involvement of synaptic pathology in this disorder.
Copyright  2012, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Schizophrenia is a complex disorder with a high degree of
genetic inﬂuence in its etiology [1]. It is nowgenerally accepted that
this illness involves variants in multiple genes that are individually
insufﬁcient to cause the illness, but which act in combination and
with environmental factors to increase the risk of development [2].
Although the majority of the genetic loci that contribute to
schizophrenia most likely have weak effects, their identiﬁcation is
essential to determining the neurobiological molecules that play
a crucial role in the disorder.
Over the past two decades, structural anomalies have been
identiﬁed in the brains of patients with schizophrenia [3]. This can
be seen in in vivo neuroimaging studies that have demonstrated
signiﬁcant ventricular enlargement and decrease in cortical mass
[4]. Postmortem brain studies have shown a reduction in the total
brain volume, particularly in the cerebral cortex [5], and functional, Buddhist Tzu Chi General
lien, Taiwan. Tel.: þ886 3
n).
ddhist Compassion Relief Tzu Chibrain-imaging studies have indicated impaired connectivity
between the frontal lobe and other brain regions [6,7]. At the
cellular and molecular level, microscopic histopathological studies
have demonstrated reduced neuronal size and decreased density of
the dendritic spines [8]. Taken together, these changes in the
synaptic components may reﬂect a decrease in the cortical volume,
and it is believed that such changes may underlie the aberrant
functional connectivity in schizophrenic patients [9,10].
For these reasons, some synaptic proteins have been utilized as
proxy markers of synapses to determine whether synaptic alter-
ations are a feature of schizophrenia [9,10]. Three such synaptic
proteins that have been repeatedly reported to be involved in
schizophrenia are synaptophysin (SYP), growth-associated protein
43 (GAP-43), and neurogranin (NRGN) [9].
2. Genetic and functional analyses of the SYP gene
in schizophrenia
SYP is an abundant integral membrane protein in the synaptic
vesicles that is expressed in 95% of cortical synaptic terminals
[11,12]. Its expression occurs early in neurogenesis and is greatly
upregulated during synaptogenesis [13]. This protein is known toFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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addition, it participates in the biogenesis and recycling of synaptic
vesicles [16,17].
Several studies have examined SYP expression in the post-
mortem brains of patients with schizophrenia. Using in situ
hybridization, histochemistry, immune autoradiography, and
Western blot analysis, decreased SYP expression has been
demonstrated in the prefrontal cortex, medial temporal cortex,
visual association cortex, hippocampus, and thalamus [18e33].
Conversely, elevated SYP protein levels have been found in the
anterior cingulate cortex [34,35]. Microarray studies have also
highlighted lower levels of SYP in the postmortem brains of
patients with schizophrenia, along with other presynaptic markers
[36]. These ﬁndings lend support to the notion that SYP distur-
bance in speciﬁc brain regions might be part of the pathogenesis of
schizophrenia [9].
The SYP gene (gene ID: 6855) has been mapped to chromosome
Xp11.23-p11.22. This region has been linked to schizophrenia
[37,38]. The function of SYP, to a large extent, is believed to be
affected by its genetic variations [39]. To test this possibility, we
searched for genetic variants in the promoter region, including all
exons and both UTR ends of the SYP gene, using direct sequencing in
a sample of patients with schizophrenia (n¼ 586) and nonpsychotic
controls (n¼ 576), all of whomwere Han Chinese from Taiwan, and
conducted further association and functional studies [40].
After sequencing all of the amplicons in the 586 patients and
576 control patients, we identiﬁed two common polymorphisms
(c.*4þ271A>G and c.*4þ565T>C) in the SYP gene. Single nucleotide
polymorphism (SNP)- and haplotype-based analyses indicated no
associations with schizophrenia. In addition, we identiﬁed six rare
variants in seven of the 586 schizophrenic patients, including one
variant (g.-511T>C) located in the promoter region, one synony-
mous (A104A) variant and two missense variants (G293A and
A324T) located in the exonic regions, and two variants (c.*31G>A
and c.*1001G>T) located at the 30UTR. No rare variants were found
in the control subjects. The results of the reporter gene assay
demonstrate the inﬂuence of g.-511T>C and c.*1001G>T on the
regulatory function of the SYP gene, while the inﬂuence of
c.*31G>A may be tolerated. In silico analysis demonstrated the
functional relevance of other rare variants. These ﬁndings lend
support to the hypothesis of multiple rare mutations in schizo-
phrenia and provide genetic clues that indicate the involvement of
SYP in this disorder.
3. Genetic and functional analyses of the GAP-43 gene in
schizophrenia
GAP-43 is a neuron-speciﬁc phosphoprotein that is localized to
the presynaptic membrane and is a substrate of protein kinase C
(PKC). Its phosphorylation by PKC in response to extracellular
guidance cues could regulate the behavior of F-actin in neuronal
growth cones [41]. In transgenic mice, overexpression of GAP-43
results in the spontaneous formation of new synapses and
enhances sprouting after injury [42,43], whereas manipulations
that abolish GAP-43 expression result in the disruption of axon
outgrowth and could lead to premature death [44,45]. GAP-43 is
expressed primarily during brain development and declines
sharply in most brain regions after synaptogenesis is completed
[41]. High levels of GAP-43 persist in neocortical-association areas
and the limbic system throughout life, where the protein might
play important roles in mediating experience-dependent synaptic
plasticity and long-term potentiation [41].
Several studies have examined GAP-43 expression in the post-
mortem brains of patients with schizophrenia. Alterations in
GAP-43 mRNA levels have been demonstrated in the dorsolateralprefrontal cortex, primary visual cortex, anterior cingulate gyrus,
and hippocampus [46e48]. Additionally, GAP-43 protein levels
have been found to be altered in the frontal cortex, visual associ-
ation cortex, and hippocampus [31,49,50]. These ﬁndings lend
support to the notion that GAP-43 disturbances in speciﬁc brain
regions might be part of the pathogenesis of schizophrenia.
The GAP-43 gene (gene ID: 2596) has been mapped to chro-
mosome 3q13.1-q13.2 [41]. This region has been linked to
schizophrenia in a Japanese single multiplex pedigree, and in
a meta-analysis of 32 genome-wide linkage studies that were
performed on different populations [51,52]. As part of our series on
molecular genetic studies on schizophrenia, we were interested in
understanding whether the GAP-43 gene plays a role in conferring
genetic liability to schizophrenia. To test this possibility, we
searched for genetic variants in the promoter region and three
exons (including both UTR ends) of the GAP-43 gene using direct
sequencing of a sample of patients with schizophrenia (n¼ 586)
and nonpsychotic controls (n¼ 576), all of who were Han Chinese
from Taiwan, and conducted further association and functional
studies [53].
After sequencing all of the amplicons of the 586 patients and
576 control patients, we identiﬁed 11 common polymorphisms in
the GAP-43 gene. SNP- and haplotype-based analyses indicated no
associations with schizophrenia. Additionally, we identiﬁed four
rare variants in ﬁve of the 586 patients, including one variant
located in the promoter region (c.-258-4722G>T) and one synon-
ymous (V110V) and two missense (G150R and P188L) variants
located on exon 2. No rare variants were found in the control
patients. The results of the reporter gene assay demonstrate that
the regulatory activities of constructs containing c.-258-4722T was
signiﬁcantly lower when compared with the wild-type construct
(c.-258-4722G). In silico analysis also demonstrated the functional
relevance of other rare variants. These ﬁndings lend support to the
hypothesis of multiple rare mutations in schizophrenia, and they
provide genetic clues that indicate the involvement of GAP-43 in
this disorder.
4. Genetic and functional analyses of the NRGN gene in
schizophrenia
NRGN is a neural-speciﬁc, calmodulin (CaM)-binding protein
localized to the postsynaptic membrane and is a substrate of PKC
[54]. Glutamate stimulation of N-methyl-D-aspartate (NMDA)
receptors results in calcium inﬂux to the neuron and NRGN
oxidation [55]. These induce dissociation of the NRGN-CaM
complex and stimulate the phosphorylation of NRGN by PKC,
which prevents the rebinding of NRGN and CaM [56]. As a CaM
reservoir, NRGN regulates the release of CaM and the activities of
downstream CaM-Ca2þ-dependent enzymes that play important
roles in the neuroplasticity mechanisms of learning and memory
[57,58]. Therefore, altering NRGN activity could mimic the effects of
NMDA-receptor hypofunction that has been suggested by several
studies, thereby implicating NRGN in the pathophysiology of
schizophrenia [59].
NRGN has been found in neurons in the cerebral cortex, hippo-
campus, striatum, and amygdala [60]. During development, NRGN
expression is regulated by thyroid hormones [61], and its highest
expression is coincident with the developmental period character-
ized by rapid dendritic growth and the formation of the majority of
the cortical synapses [62]. Broadbelt et al. (2006) examined NRGN
expression in the postmortem brains of patients with schizophrenia.
Lowered NRGN immunoreactivity was demonstrated in areas 9 and
32 of the schizophrenic prefrontal cortex [63]. Therefore, NRGN
disturbance in speciﬁc brain regions might be part of the patho-
genesis in schizophrenia.
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SNP (rs12807809) located upstream of the NRGN gene that is
associated with schizophrenia [64,65], but causal variants that
account for the association signal have not been determined. GWA
data usually indicate the indirect association of a proxy of a strongly
correlated causal variant that has a similar frequency or synthetic
association with one or more rarer causal variants in the linkage
disequilibrium [66,67]. Causal variants require extensive rese-
quencing and association analysis. In order to ﬁnd the causal vari-
ants of the NRGN gene associated with schizophrenia, we searched
for genetic variants in the promoter region and all exons (including
both UTR ends and rs12807809) using direct sequencing in a sample
of patients with schizophrenia (n¼ 346) and nonpsychotic controls
(n¼ 345), all of whom were Han Chinese from Taiwan, and con-
ducted further association and functional studies [68].
After sequencing all the amplicons of the 346 patients and 345
control subjects, we identiﬁed seven common polymorphisms in
the NRGN gene. SNP- and haplotype-based analyses indicated no
associations with schizophrenia. Additionally, we identiﬁed ﬁve rare
variants in six of the 346 patients, including three rare variants
located in the promoter region (g.-620A>G, g.-578C>G, and g.-
344G>A) and two rare variants located at 50UTR (c.-74C>G, and
c.-41G>A). No rare variants were found in the control patients. The
results of the reporter gene assay demonstrate that the regulatory
activities of constructs containing g.-620G, g.-578G, g.-344A, c.-74G,
or c.-41A are signiﬁcantly lower when compared to the wild-type
construct. In silico analysis also demonstrated their inﬂuence on
the regulatory function of the NRGN gene. These data also lend
support to the hypothesis that multiple rare mutations are involved
in schizophrenia, and provide genetic clues that indicate the
involvement of NRGN in this disorder.
5. Summary and future research
In our series of genetic studies of schizophrenia, we used
a resequencing strategy to search for genetic variants in each
candidate gene in a sample of schizophrenic and control patients,
and assessed their associations with schizophrenia. Three candi-
date genes related to synaptic pathology in schizophrenia were
resequenced, but no common polymorphisms appeared to play
a major role in conferring susceptibility to schizophrenia in our
population. Additionally, we identiﬁed some rare patient-speciﬁc
variants. The results of reporter gene assays and software analysis
demonstrate the inﬂuence of reporter genes on the function of each
studied gene, suggesting that they may contribute to the patho-
genesis of schizophrenia.
Our ﬁndings support the “common disease, rare alleles” model
for explaining some cases of schizophrenia [69]. The hypothesis is
that the many mutations that predispose an individual to devel-
oping schizophrenia are highly penetrant and individually rare,
sometimes even speciﬁc to a single patient or family. In this model,
different patients harbored different mutations, either in the same
gene or in different genes, but each one carried only one or two
mutations. Given the fact that these individually rare variants
may not contribute, to a signiﬁcant degree, to the heritability of
schizophrenia, their discovery is likely to be much more rewarding
than that of common polymorphisms in terms of practical appli-
cations, including our understanding schizophrenia’s etiology.
After identifying these rare patient-speciﬁc variants that are
related to synaptic pathology, family studies on the patients with
these rare variants should be conducted in order to clarify their
inheritance model, genotype/phenotype correlation, phenotypic
variability, and penetrance rate. Furthermore, cell-based and elec-
trophysiological experiments are warranted to verify their inﬂu-
ence on signal transduction, membrane potential, cell proliferation,migration, and differentiation (e.g., axonal outgrowth, dendrite
branching, and synaptogenesis). Furthermore, these ﬁndings will
be essential to the development of model animals, further patho-
genic studies, and novel drugs that could be used to treat this
devastating disorder.
It is noteworthy that the targeted resequencing of genes has
been used to successfully ﬁnd associations between rare variants
with quantitative traits. However, this approach is currently limited
to selected candidate genes. Recently, massive parallel-sequencing
technologies, in conjunction with new DNA-enrichment technolo-
gies (e.g., exome capture), have been developed that allow the
sequencing of targeted regions in large samples of the human
genome [70]. In addition, exome capture allows unbiased investi-
gations into complete protein-coding regions of the genome.
Because rare variants are usually associated with a high rate of
penetrance, they may be much more likely to become the basis for
some sort of personalized medicine than those usually discussed in
relation to the common polymorphisms.Acknowledgments
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